Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia.

Sillaber, C; Mayerhofer, M; Böhm, A; Vales, A; Gruze, A; Aichberger, K J; Esterbauer, H; Pfeilstöcker, M; Sperr, W R; Pickl, W F; Haas, O A; Valent, P

Sillaber, C; Mayerhofer, M; Böhm, A; Vales, A; Gruze, A; Aichberger, K J; Esterbauer, H; Pfeilstöcker, M; Sperr, W R; Pickl, W F; Haas, O A; Valent, P.

Affiliation

Sillaber C; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.

Eur J Clin Invest ; 38(1): 43-52, 2008 Jan.

Article in En | MEDLINE | ID: mdl-18173550

Subject(s)

Antibiotics, Antineoplastic/therapeutic use; Antineoplastic Agents/therapeutic use; Leukemia, Myeloid, Chronic-Phase/drug therapy; Piperazines/therapeutic use; Pyrimidines/therapeutic use; Sirolimus/therapeutic use; Aged; Benzamides; Drug Evaluation; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Pilot Projects; RNA, Messenger/metabolism; RNA, Neoplasm/metabolism; Treatment Outcome; Vascular Endothelial Growth Factor A/metabolism

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Pyrimidines / Leukemia, Myeloid, Chronic-Phase / Sirolimus / Antibiotics, Antineoplastic / Antineoplastic Agents Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Eur J Clin Invest Year: 2008 Document type: Article Affiliation country: Austria Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google